Microscopic Polyangiitis (MPA) is a rare autoimmune small-vessel vasculitis that falls under the family of ANCA-associated vasculitides, along with GPA and EGPA. It leads to inflammation and damage in capillaries, venules, and arterioles, most commonly affecting the kidneys, lungs, skin, nerves, and joints.
MPA is strongly linked with p-ANCA positivity, especially MPO-ANCA, and arises from complex interactions involving genetic predisposition, environmental triggers, and immune dysregulation.
Symptoms range from persistent fever, fatigue, weight loss, skin rashes, and joint pain to severe complications such as hemoptysis and rapidly progressive glomerulonephritis.
Diagnosis relies on ANCA testing, imaging, urinalysis, and confirmatory tissue biopsy. Without timely treatment, MPA can progress rapidly and become life-threatening. Standard management includes high-dose corticosteroids and immunosuppressants such as cyclophosphamide or rituximab for induction, followed by maintenance therapies like azathioprine or methotrexate.
Recently, targeted therapies particularly complement C5a receptor inhibitors such as avacopan have gained traction for reducing steroid dependence and improving long-term outcomes.
According to BIS Research, the global Microscopic Polyangiitis market is projected to grow steadily from 2025 to 2035, driven by biologics, precision medicine, and improved disease management pathways.
Explore the full TOC and Book a Preview
• Increasing adoption of biologic therapies for targeted and improved disease control
• Advancements in optimized immunosuppressive treatment regimens
• Growing clinical evidence supporting early diagnosis and intervention
• Rising investments in next-generation biologics, biosimilars, and precision-based treatment
• Expanding access to advanced therapies in emerging markets
According to BIS Research analysts:
“The Microscopic Polyangiitis (MPA) market is entering a transformative phase as biologic-first strategies become mainstream. With rising adoption of rituximab, complement inhibitors, and precision-based therapies, the treatment landscape is shifting toward targeted, safer, and more effective interventions. Expanding pipelines, improving diagnostics, and growing investments across emerging economies position the MPA market for sustained therapeutic innovation through 2035.”
The market is expected to grow steadily through 2035, driven by biologics, precision medicine, and expanding availability of advanced therapies.
Major companies include:
Roche, Amgen Inc., Teva Pharmaceuticals Inc., Novartis AG, Baxter, Amerigen Pharmaceuticals, InflaRx N.V., Biogen Inc., Pfizer, and Celltrion.
Biologic therapies particularly rituximab and emerging complement pathway inhibitors are leading demand due to better safety profiles and reduced relapse rates.
BIS Research KOL-based insights provides deep-dive insights, granular segmentation, and advisory support across immunology, rare diseases, and advanced therapeutic development.
[Contact Analyst]
[Download TOC]
